Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $115.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings’s rating is based on Boston Scientific’s strong performance expectations and solid growth prospects. He anticipates the company will surpass its first-quarter estimates, driven by robust demand for key products like Farapulse and Watchman. Jennings believes that Boston Scientific will either maintain or raise its 2025 organic sales growth guidance, which currently stands at 10-12%, and reiterate its EPS guidance of $2.80-$2.87.
The confidence in Boston Scientific’s ability to sustain top-tier sales growth is further supported by positive operating momentum and favorable reports from peer companies like JNJ and ABT. The company is expected to keep its guidance intact, with potential upside in sales growth, and its strategic positioning suggests resilience against external pressures such as tariffs. These factors collectively contribute to Jennings’s Buy rating for Boston Scientific.
Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Boston Scientific, and Johnson & Johnson. According to TipRanks, Jennings has an average return of 0.2% and a 45.47% success rate on recommended stocks.
In another report released on April 16, Needham also upgraded the stock to a Buy with a $113.00 price target.